Debt-free Balance SheetElimination of interest-bearing debt materially improves financial flexibility and reduces default risk. A zero-debt position lengthens runway for a small biotech, enabling R&D or strategic spending without immediate refinancing, and it strengthens credit capacity for future partnerships or licensing deals.

Very High Gross MarginsSustained ~97% gross margins indicate a highly scalable cost structure or premium product pricing, giving the company large operating leverage potential. If topline stabilizes or grows, these margins can convert revenue expansion into durable operating profitability over the medium term.

Return To Net ProfitabilityNet income turning positive shows progress toward sustainable earnings after prior losses. Combined with stronger equity and an improving ROE backdrop, this suggests management is beginning to extract value from operations, though continued progress is needed to ensure permanence.

Bears Say

Persistent Negative Cash FlowContinued negative operating and free cash flow means the business is not self-funding and remains dependent on external financing or asset sales. Over months, persistent cash burn constrains R&D spending choices, dilutes optionality, and raises execution risk if capital markets tighten.

Negative Operating Profitability (EBIT)Losses at the EBIT level imply core operations are not yet profitable and recent net income gains may include one-offs or non-operating items. This undermines earnings durability: if non-recurring benefits reverse, the company could revert to operating losses and need renewed external funding.

Declining Revenue TrendA shrinking top line reduces the ability to leverage high gross margins into operating profit and signals demand or commercial execution challenges. For a small biotech, revenue decline complicates scale-up plans and increases reliance on financing or partnerships to support long-term growth.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥868.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥26.80B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is May 07, 2026 which is in 58 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Feb 13, 2026. The company reported -¥5.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.21.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,250,100 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.626%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.